FLT3-ITD F692L + NPM1 mutation	Acute Myelogenous Leukemia	FLT3-ITD F692L + NPM1 mutation	Acute Myelogenous Leukemia	ponatinib + MI-503 Sensitive: D – Preclinical ponatinib + MI-503 Sensitive : D	ponatinib + MI-503 Sensitive: D – Preclinical ponatinib + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	gilteritinib + MI-503 Sensitive: D – Preclinical gilteritinib + MI-503 Sensitive : D	gilteritinib + MI-503 Sensitive: D – Preclinical gilteritinib + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D	ARO-002 + MI-503 Sensitive: D – Preclinical ARO-002 + MI-503 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D

MI-503

Associations
(4)